The Inhibrx Management Team

Mark P. Lappe
Mark P. Lappe

Founder, Chief Executive Officer

Brendan P. Eckelman, Ph.D.
Brendan P. Eckelman, Ph.D.

Founder, EVP Chief Scientific Officer

Kelly Deck, C.P.A.
Kelly Deck, C.P.A.

EVP, Chief Financial Officer

Ashraf Amanullah, Ph.D.
Ashraf Amanullah, Ph.D.

EVP, Chief Technical Operations Officer

David Matly, M.B.A.
David Matly, M.B.A.

EVP, Chief Commercial and Business Development Officer

Josep Garcia, Ph.D.
Josep Garcia, Ph.D.

EVP, Chief Clinical Development Officer

Carlos Bais, Ph.D.
Carlos Bais, Ph.D.

EVP, Translational Sciences

Leah Pollema, J.D.
Leah Pollema, J.D.

VP, General Counsel

David Kao, PharmD, M.B.A., RPh
David Kao, PharmD, M.B.A., RPh

VP, Regulatory Affairs

Robert Boothroyd, PharmD
Robert Boothroyd, PharmD

VP, Medical Affairs and Business Development

Dana Ebbets-Reed, Ph.D.
Dana Ebbets-Reed, Ph.D.

VP, Quality Assurance

Darren Brown, Ph.D.
Darren Brown, Ph.D.

VP, Analytical Development and Quality Control

Brian Lobo, Ph.D.
Brian Lobo, Ph.D.

VP, Formulation Development and Drug Product Manufacturing

Melissa Masterson
Melissa Masterson

VP, Value, Access and Distribution

The Inhibrx Board

Mark P. Lappe

Chairman

Douglas G. Forsyth

Director

Jon Faiz Kayyem, Ph.D.

Director

Kimberly Manhard

Director

Kristiina Vuori, M.D., Ph.D.

Director

The INBRX-101 Scientific Advisory Board

Igor Barjaktarevic, M.D., Ph.D.

Mark Brantly, M.D.

Kenneth R. Chapman, M.D., MSc, FRCPC, FACP, FERS

Noel Gerry McElvaney, M.D., BCh, BAO, FRCPI, FRCPC

Robert A. Sandhaus, M.D., Ph.D., FCCP

James Stoller, M.D., M.S.